New Agents To Invade UC Market As Biosimilars Put Pressure On Stalwarts

 
• By Lucie Ellis-Taitt

The ulcerative colitis pipeline is bustling with novel drugs, with new modes of action, that are ready to take on the market leading biologic therapies and their biosimilar counterparts; five launches are anticipated from four different drug classes before 2022.

Colitis
Ulcerative colitis market under the microscope: new drugs are emerging to challenge anti-TNF class • Source: Shutterstock

More from Immunological

More from Therapy Areas